Complete financial analysis of Solid Biosciences Inc. (SLDB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Solid Biosciences Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rabigh Refining and Petrochemical Company (2380.SR) Income Statement Analysis – Financial Results
- Whirlpool of India Limited (WHIRLPOOL.NS) Income Statement Analysis – Financial Results
- Odawara Engineering Co., Ltd. (6149.T) Income Statement Analysis – Financial Results
- EnGold Mines Ltd. (GWRRF) Income Statement Analysis – Financial Results
- The Sumitomo Warehouse Co., Ltd. (9303.T) Income Statement Analysis – Financial Results
Solid Biosciences Inc. (SLDB)
About Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 8.09M | 13.62M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 76.56M | 2.41M | 58.74M | 3.92M | 2.82M | 1.57M | 448.00K | 56.00K | 0.00 |
| Gross Profit | -76.56M | 5.69M | -45.12M | -3.92M | -2.82M | -1.57M | -448.00K | -56.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 70.25% | -331.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 76.56M | 78.42M | 58.74M | 64.88M | 94.74M | 57.97M | 39.91M | 20.12M | 4.19M |
| General & Administrative | 27.75M | 28.95M | 27.14M | 21.58M | 24.58M | 17.72M | 14.95M | 5.46M | 2.37M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.75M | 28.95M | 27.14M | 21.58M | 24.58M | 17.72M | 14.95M | 5.46M | 2.37M |
| Other Expenses | 0.00 | -381.00K | 2.00K | 1.94M | 515.00K | 270.00K | 1.46M | 1.43M | -103.00K |
| Operating Expenses | 104.32M | 107.37M | 85.87M | 86.46M | 119.32M | 75.69M | 54.86M | 25.58M | 6.56M |
| Cost & Expenses | 104.32M | 107.37M | 85.87M | 86.46M | 119.32M | 75.69M | 54.86M | 25.58M | 6.56M |
| Interest Income | 7.14M | 2.62M | 64.00K | 115.00K | 1.58M | 619.00K | 219.00K | 369.00K | 3.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.58M | 2.41M | 2.96M | 3.92M | 2.82M | 1.57M | 448.00K | 56.00K | 6.56M |
| EBITDA | -93.43M | -96.87M | -69.29M | -84.37M | -116.49M | -75.69M | -54.41M | -25.52M | 119.00K |
| EBITDA Ratio | 0.00% | -1,333.38% | -508.74% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -104.32M | -106.45M | -72.25M | -88.41M | -119.32M | -75.69M | -54.86M | -25.58M | -6.56M |
| Operating Income Ratio | 0.00% | -1,315.20% | -530.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.30M | 20.47M | 66.00K | -1.83M | 2.10M | 889.00K | 1.68M | 1.80M | -100.00K |
| Income Before Tax | -96.02M | -85.98M | -72.19M | -88.29M | -117.22M | -74.80M | -53.18M | -23.77M | -6.66M |
| Income Before Tax Ratio | 0.00% | -1,062.28% | -530.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -20.47M | -64.00K | 1.83M | -1.58M | 889.00K | -1.28M | -2.60M | -287.00K |
| Net Income | -96.02M | -65.51M | -72.12M | -90.12M | -115.64M | -74.80M | -52.12M | -21.54M | -6.38M |
| Net Income Ratio | 0.00% | -809.36% | -529.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.83 | -7.70 | -10.13 | -26.03 | -43.05 | -33.73 | -24.26 | -16.80 | -4.97 |
| EPS Diluted | -4.83 | -7.70 | -10.13 | -26.03 | -43.05 | -33.73 | -24.26 | -16.80 | -4.97 |
| Weighted Avg Shares Out | 19.88M | 8.51M | 7.12M | 3.46M | 2.69M | 2.22M | 2.15M | 1.28M | 1.28M |
| Weighted Avg Shares Out (Dil) | 19.88M | 8.51M | 7.12M | 3.46M | 2.69M | 2.22M | 2.15M | 1.28M | 1.28M |
Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer
CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed Chief Financial Officer and...
Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer
CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the appointment of Kevin Tan, CFA, a seasoned industry professional, as Chief Financial...
Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 41st...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for patients with neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed...
Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement
- Transactions create a precision genetic medicine company focused on neuromuscular and cardiac diseases, led by industry veteran Bo Cumbo -
Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio
- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases -
SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Solid Biosciences Inc. (“the Company”) (NasdaqGS: SLDB) with AavantiBio, Inc. pursuant...
SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB
NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Solid Biosciences Inc. (“the Company”) (NasdaqGS: SLDB) with AavantiBio,...
Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Lags Revenue Estimates
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.63% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results
- Recently presented preclinical data support potential benefits of next-generation Duchenne gene therapy candidate SGT-003; program on track for mid-2023 Investigational New Drug (IND) submission -
Source: https://incomestatements.info
Category: Stock Reports